Seoul National University Bundang Hospital is located in Gumi-dong, Bundang, Seongnam, Gyeonggi-do, South Korea. It began its first treatment on 10 May 2003.

During the past decade, Seoul National University Bundang Hospital conducted 821 clinical trials. In the 10-year time frame, 821 clinical trials started and 172 clinical trials were completed, i.e. on average, 21% percent of trials that started reached the finish line to date. In the past 5 years, 389 clinical trials started and 124 clinical trials were completed. i.e. 31.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Seoul National University Bundang Hospital" #1 sponsor was "Seoul National University Bundang Hospital" with 229 trials, followed by "Seoul National University Hospital" with 220 trials sponsored, "Hoffmann-La Roche" with 66 trials sponsored, "Pfizer" with 34 trials sponsored and "Janssen Research & Development, LLC" with 34 trials sponsored. Other sponsors include 527 different institutions and companies that sponsored additional 241 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Seoul National University Bundang Hospital" #1 collaborator was "Seoul National University Bundang Hospital" with 57 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 19 trials as a collaborator, "AstraZeneca" with 14 trials as a collaborator, "CardioVascular Research Foundation, Korea" with 11 trials as a collaborator and "Ministry of Health & Welfare, Korea" with 11 trials as a collaborator. Other collaborators include 558 different institutions and companies that were collaborators in the rest 289 trials.

According to Clinical.Site data, the most researched conditions in "Seoul National University Bundang Hospital" are "Gastric Cancer" (34 trials), "Coronary Artery Disease" (24 trials), "Breast Cancer" (23 trials), "Healthy" (19 trials) and "Carcinoma, Non-Small-Cell Lung" (18 trials). Many other conditions were trialed in "Seoul National University Bundang Hospital" in a lesser frequency.

Most popular intervention types in "Seoul National University Bundang Hospital" are "Drug" (735 trials), "Device" (131 trials), "Other" (102 trials), "Procedure" (86 trials) and "Biological" (52 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (162 trials), "Paclitaxel" (36 trials), "Carboplatin" (30 trials), "Cisplatin" (26 trials) and "Atezolizumab" (25 trials). Other intervention names were less common.

The vast majority of trials in "Seoul National University Bundang Hospital" are 985 trials for "All" genders, 73 trials for "Female" genders and 47 trials for "Male" genders.

Currently, there are 381 active trials in "Seoul National University Bundang Hospital". 2 are not yet recruiting, 230 are recruiting, 147 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 513 completed trials in Seoul National University Bundang Hospital, undefined suspended trials, and 70 terminated clinical trials to date.

Out of the total trials that were conducted in Seoul National University Bundang Hospital, 113 "Phase 1" clinical trials were conducted, 204 "Phase 2" clinical trials and 345 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 106 trials, and there were also 224 trials that are defined as “Not Applicable".

Seoul National University Bundang Hospital has several departments that took part in Clinical trials: "Department of Obstetrics and Gynecology Seoul National University Bundang Hospital" - 8 trials, "Seoul National University Bundang Hospital, Department of Neurology" - 4 trials, "Seoul National University Bundang Hospital - Division of Infectious Diseases" - 3 trials, "Seoul National University Bundang Hospital, Clinical Pharmacy" - 2 trials